insulin glargine sold brand name lantus among others longacting modified form medical insulin used management type type ii injected effects generally begin hour common side effects include low blood sugar problems site injection itchiness weight serious side effects include low blood nph insulin rather insulin glargine generally preferred injection microcrystals slowly release insulin insulin causes body tissues absorb glucose blood decreases glucose production insulin glargine approved medical use united states world health organizations list essential commonly prescribed medication united states million july us food drug administration fda approved interchangeable biosimilar insulin product called semglee insulin glargineyfgn treatment longacting insulin class includes insulin glargine appear much better neutral protamine hagedorn nph greater cost making cost effective treatment type previous review unclear difference hypoglycemia enough data determine differences respect long term however recent cochrane systematic review find clinically significant difference comparing insulin glargine nph insulin insulin detemir insulin degludec management type diabetes neither adults children periods months typically recommended long acting insulin united semglee indicated improve glycemic control adults children type diabetes adults type semglee biosimilar interchangeable substituted reference product lantus insulin glargine longacting insulin unlike longeracting insulins glargine must diluted mixed insulin solution however restriction common side effects include low blood sugar problems site injection itchiness weight serious side effects include low blood tentative evidence shows association insulin glargine previous studies raised comparing insulin glargine nph insulin insulin detemir insulin degludec significant adverse effects found management type diabetes neither adults children periods months insulin glargine differs human insulin replacing asparagine glycine position achain carboxyterminal extension bchain arginine residues arginine amino acids shift isoelectric point ph making molecule soluble acidic ph less soluble physiological ph isoelectric shift also allows subcutaneous injection clear solution glycine substitution prevents deamidation acidsensitive asparagine acidic ph neutral subcutaneous space higherorder aggregates form resulting slow peakless dissolution absorption insulin site achieve peakless level least hours insulin glargine formulated acidic ph completely watersoluble subcutaneous injection acidic solute cause discomfort stinging sensation physiologic ph approximately achieved increase ph causes insulin come solution resulting formation higher order aggregates insulin hexamers higher order aggregation slows dissociation hexamers insulin monomers functional physiologically active unit insulin gradual process ensures small amounts insulin glargine released body continuously giving almost peakless profile june european commission formally approved launching lantus sanofiaventis germany ltd entire european admission prolonged june threefold concentrated formulation brand name toujeo introduced fda approval abasaglar approved medical use european union september lusduna approved medical use european union january march insulin glargine semglee approved medical use european july insulin glargineyfgn semglee approved medical use united states first interchangeable biosimilar fda granted approval semglee mylan pharmaceuticals patent protection insulin glargine expired countries needed usa expected expire insulin glargine competitor eli lilly became available countries brand names basaglar followon us abasaglar biosimilar eucitation needed httpsenwikipediaorgwikiinsulinglargine